A comprehensive market analysis report on atherectomy devices covering 39 countries with forecasts through 2036. The market is driven by the shift toward minimally-invasive techniques for treating coronary and peripheral artery diseases, replacing traditional bypass surgery. The report provides detailed market segmentation, intervention volumes, competitive dynamics, and regulatory insights across developed markets.

AngioDynamics shares fell 13.1% despite posting strong Q3 results with revenue of $79.4 million (beating estimates) and better-than-expected earnings. The sell-off was triggered by the unexpected announcement of CEO Jim Clemmer's retirement after 10 years leading the company. While the board has formed a search committee to find a successor and the company raised its 2026 guidance, investor uncertainty about leadership transition overshadowed the positive business fundamentals.

AngioDynamics reported Q1 fiscal 2026 results with mixed performance, beating adjusted earnings expectations but showing ongoing challenges in profitability. The company saw 12% overall sales growth, driven by med tech segment, but remains years away from consistent profitability.

Insiders have been making significant purchases in Eton Pharmaceuticals, AngioDynamics, and Tile Shop Holdings, indicating their confidence in these companies' prospects.

AngioDynamics (ANGO) has seen a 15.9% decline in the past four weeks, but its oversold RSI and improved earnings estimates suggest a potential turnaround may be on the horizon.

AngioDynamics, a medical technology company, reported mixed results for its fiscal Q1, with revenue slightly missing estimates but adjusted loss per share better than expected. The company maintained its full-year guidance, but its growth prospects are not seen as exciting compared to other stocks.

Oppenheimer raised its price target for AngioDynamics stock to $13 from $12, citing the company's strong fourth-quarter sales, particularly in its higher-margin and growth segments. The firm also noted AngioDynamics' efforts to expand EBITDA and reach profitability by fiscal year 2027.

The U.S. autoimmune disease diagnostics market is expected to reach $3.01 billion by 2030, driven by the rising incidence of autoimmune diseases and advancements in diagnostic technologies. Localized autoimmune disease diagnostics and antinuclear antibody tests are expected to dominate the market.

AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.

Although U.S. stocks closed little changed on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Semtech The Trade: Semtech Corporation (NASDAQ: SMTC) EVP and CFO Mark Lin acquired a total of 1,000 shares an average price of $33.23. To acquire these shares, it cost around $33,232. What’s Happening: On March 28, ...

Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.

AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.